{
    "clinical_study": {
        "@rank": "52051", 
        "arm_group": {
            "arm_group_label": "Busulfan", 
            "arm_group_type": "Experimental", 
            "description": "First dose: busulfan (120 mg/m2 ivs once daily) (if age<1 yr: 80 mg/ m2) Second to forth dose: according to the daily pharmacokinetic study"
        }, 
        "brief_summary": {
            "textblock": "To evaluate the outcome of hematopoietic stem cell transplantation using targeted busulfan,\n      fludarabine conditioning regimen in genetic rare disease"
        }, 
        "brief_title": "Targeted Busulfan, Fludarabine Conditioning Regimen for Hematopoietic Stem Cell Transplantation in GRD", 
        "completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Genetic Rare Disease", 
        "condition_browse": {
            "mesh_term": "Rare Diseases"
        }, 
        "detailed_description": {
            "textblock": "Busulfan is a highly toxic drug with narrow therapeutic window used for the conditioning of\n      hematopoietic stem cell transplantation. High exposure is associated with systemic toxicity\n      such as veno-occlusive disease (VOD) and underexposure is associated with graft failure or\n      relapse. In this study the investigators plan to improve the outcome of hematopoietic stem\n      cell transplantation by using optimal busulfan dose through pharmacokinetic study."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Patients who are diagnosed as genetic rare disease.\n\n          2. Patients who need hematopoietic stem cell transplantation\n\n          3. Age: up to 21 years\n\n          4. Performance status: ECOG 0-2.\n\n          5. Patients must be free of significant functional deficits in major organs, but the\n             following eligibility criteria may be modified in individual cases. 1. Heart: a\n             shortening fraction > 30% and ejection fraction > 45%. 2. Liver: total bilirubin < 2\n             \u00d7 upper limit of normal; ALT < 3 \u00d7 upper limit of normal. 3. Kidney: creatinine <2 \u00d7\n             normal or a creatinine clearance (GFR) > 60 ml/min/1.73m2.\n\n          6. Patients must lack any active viral infections or active fungal infection.\n\n          7. Appropriate donor is available: Matched in 6/6 of A, B, DR loci.\n\n          8. Patients (or one of parents if patients age < 19) should sign informed consent.\n\n        Exclusion Criteria:\n\n          1. Pregnant or nursing women.\n\n          2. Malignant or nonmalignant illness that is uncontrolled or whose control may be\n             jeopardized by complications of study therapy.\n\n          3. Psychiatric disorder that would preclude compliance."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "21 Years", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "5", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 9, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02034630", 
            "org_study_id": "SNUCH_GRDBuFlu"
        }, 
        "intervention": {
            "arm_group_label": "Busulfan", 
            "description": "First dose: busulfan (120 mg/m2 ivs once daily) (if age<1 yr: 80 mg/ m2) Second to forth dose: according to the daily pharmacokinetic study", 
            "intervention_name": "Busulfan", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Busulfan", 
                "Fludarabine"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": "hematopoietic stem cell transplantation", 
        "lastchanged_date": "January 10, 2014", 
        "location": {
            "contact": {
                "email": "kanghj@snu.ac.kr", 
                "last_name": "Hyoung Jin Kang, MD, PhD", 
                "phone": "82 2 2072 3304"
            }, 
            "contact_backup": {
                "email": "agnesjw@hanmail.net", 
                "last_name": "Ji Won Lee, MD", 
                "phone": "82 2 2072 3452"
            }, 
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of", 
                    "state": "Daehangno, Jongno-gu"
                }, 
                "name": "Seoul National University Hospital"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "1", 
        "official_title": "Targeted Busulfan, Fludarabine Conditioning Regimen for Hematopoietic Stem Cell Transplantation in Genetic Rare Disease", 
        "other_outcome": [
            {
                "description": "To evaluate survival rate", 
                "measure": "To evaluate survival rate", 
                "safety_issue": "No", 
                "time_frame": "1, 3, 6 and 12 months after transplantation"
            }, 
            {
                "description": "To evaluate toxicities associated with hematopoietic stem cell transplantation", 
                "measure": "To evaluate toxicities associated with hematopoietic stem cell transplantation", 
                "safety_issue": "No", 
                "time_frame": "1, 3, 6 and 12 months after transplantation"
            }, 
            {
                "description": "To evaluate acute GVHD", 
                "measure": "To evaluate acute GVHD", 
                "safety_issue": "No", 
                "time_frame": "1, 3, 6 and 12 months after transplantation"
            }, 
            {
                "description": "To evaluate chronic GVHD", 
                "measure": "To evaluate chronic GVHD", 
                "safety_issue": "No", 
                "time_frame": "1, 3, 6 and 12 months after transplantation"
            }
        ], 
        "overall_contact": {
            "email": "kanghj@snu.ac.kr", 
            "last_name": "Hyoung Jin Kang, MD, PhD", 
            "phone": "82 2 2072 3304"
        }, 
        "overall_contact_backup": {
            "email": "agnesjw@hanmail.net", 
            "last_name": "Ji Won Lee, MD", 
            "phone": "82 2 2072 4192"
        }, 
        "overall_official": {
            "affiliation": "Seoul National University Hospital", 
            "last_name": "Hyoung Jin Kang, M.D., Ph.D", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Korea: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To evaluate engraftment rate", 
            "measure": "To evaluate engraftment rate", 
            "safety_issue": "Yes", 
            "time_frame": "1 year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02034630"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "To evaluate treatment related mortality", 
            "measure": "To evaluate treatment related mortality", 
            "safety_issue": "Yes", 
            "time_frame": "1 year"
        }, 
        "source": "Seoul National University Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Seoul National University Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}